Why Neumora Therapeutics, Inc.’s (NMRA) Stock Is Down 5.47%
As of Wednesday, September 23, Neumora Therapeutics, Inc.’s NMRA share price has dipped by 5.47%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Stock Evaluator: Neumora Therapeutics, Inc. (NMRA)
Neumora Therapeutics, Inc. NMRA
$0.73
-0.05
-6.06%
September 23, 2026 4:00:00 PM
EST
Volume: 1,689,754
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders. In addition, the company’s preclinical phase product includes NMRA-GCase, an activator program for the treatment of Parkinson’s Disease; NMRA-CK1d, a casein kinase 1 isoform delta (CK1d) inhibitor program for Amyotrophic Lateral Sclerosis; and NMRA-215 a brain-penetrant oral NLRP3 inhibitor for the treatment of obesity. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Commentary & Analysis
Why Neumora Therapeutics, Inc.’s (NMRA) Stock Is Up 6.84%
As of Tuesday, September 22, Neumora Therapeutics, Inc.’s NMRA share price has surged by 6.84%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Neumora Therapeutics, Inc.’s (NMRA) Stock Is Up 5.87%
As of Wednesday, September 16, Neumora Therapeutics, Inc.’s NMRA share price has surged by 5.87%, which has investors questioning if this is right time to sell.Michael Rose
Why Neumora Therapeutics, Inc.’s (NMRA) Stock Is Down 8.58%
As of Tuesday, September 15, Neumora Therapeutics, Inc.’s NMRA share price has dipped by 8.58%, which has investors questioning if this is right time to buy.Michael Rose
Why Neumora Therapeutics, Inc.’s (NMRA) Stock Is Down 7.46%
As of Friday, September 11, Neumora Therapeutics, Inc.’s NMRA share price has dipped by 7.46%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | NMRA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $138.0 | $559.1 | 24% |
|
| Shares Out (Mil) | 185.2 | 42.7 | 74% |
|
| Institutional Ownership | 90.2% | 83.7% | 58% |
|
| Float (Mil) | 116.4 | 45.1 | 64% |
|
| Beta | 2.78 | 0.72 | 97% |
|
| Avg Daily Volume (000s) | 2,156 | 397 | 81% |
|
| Price Change (52-week) |
(57.5%) | 63.3% | 14% |
|
| Growth | NMRA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.4% | na |
|
| Net Income (5yr) | (19.0%) | (1.4%) | 21% |
|
| EPS (5yr) | 28.3% | 15.1% | 79 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (56.1%) | (15.0%) | 5% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 9 | 9 | 9 | |
| Current EPS | ($0.192) | ($0.872) | ($0.669) | |
| Month Ago EPS | ($0.192) | ($0.872) | ($0.669) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.207) | ($0.920) | ($0.774) | |
| Year/Year Chg | (17.6%) | (39.9%) | (54.6%) | |
| Financials | NMRA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $317 | na |
|
| Net Income (TTM) (Mil) | ($213) | ($11) | 6% |
|
| EPS (TTM) | ($1.224) | ($0.600) | 19% |
|
| Operating Cash Flow (TTM) (Mil) | ($181) | ($6) | 4% |
|
| Net Cash Flow (TTM) (Mil) | ($8) | $5 | 32% |
|
| Long-Term Debt (Q1) (Mil) | $53 | $6 | 39% |
|
| Enterprise Value (Q1) (Mil) | $237 | $493 | 27% |
|
| Valuation | NMRA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.06 | 2.40 | 67% |
|
| P/E | na | 16.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | NMRA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.4% | na |
|
| Net Margin | na | 2.5% | na |
|
| ROA | (121.9%) | (22.0%) | 4% |
|
| ROE | (187.1%) | (21.8%) | 4% |
|
| Liabilities to Assets | 64.5% | 32.6% | 59% |
|
| F-Score | 1 | 3 | 1% |
|
Neumora Therapeutics, Inc. did not pass any screens on 9/23/2026.
